3 Lucrative Stocks That Still Raise Some Questions

Profitability Isn’t the Whole Story

While earning profits is crucial for any business, it doesn’t always ensure lasting success. Companies that become complacent with their profit margins may find themselves overtaken as competition heats up. As Jeff Bezos famously put it, "Your margin is my opportunity."

Although strong earnings are important, they aren’t the only factor to consider. At StockStory, our mission is to help you spot businesses with genuine long-term potential. With that in mind, let’s look at three profitable companies we believe you should avoid, along with some more promising alternatives.

Somnigroup (SGI)

Latest 12-Month GAAP Operating Margin: 10.1%

Formed by the 2012 merger of Tempur-Pedic and Sealy, Somnigroup (NYSE:SGI) is a leading bedding company, recognized for its cutting-edge memory foam mattresses and sleep-related products.

Reasons We’re Not Bullish on SGI:

• Over the past five years, SGI’s annual revenue growth of 15.3% has lagged behind other consumer discretionary companies.
• The company’s free cash flow margin is projected to remain unchanged in the coming year.
• Returns on capital have declined from an already low base, highlighting ineffective investment decisions by management.

Currently, Somnigroup trades at $80.02 per share, reflecting a forward P/E of 25. Read our comprehensive research report to see why SGI doesn’t meet our standards.

Integra LifeSciences (IART)

Latest 12-Month GAAP Operating Margin: 9.7%

Founded in 1989, Integra LifeSciences (NASDAQ:IART) has been a trailblazer in regenerative medicine, producing technologies for neurosurgery, wound care, and surgical reconstruction, including innovative tissue products and surgical tools.

Why We’re Cautious About IART:

• Organic revenue growth has missed our benchmarks over the last two years, suggesting a need for improvements in products, pricing, or market approach.
• Free cash flow margin has dropped by 19 percentage points over five years, indicating heavy investment to maintain its market position.
• A net-debt-to-EBITDA ratio of 6× signals high leverage, raising the risk of shareholder dilution if the company faces unexpected challenges.

Integra LifeSciences is priced at $9.61 per share, with a forward P/E of 4.2. Check out our free research report to learn why IART may not be the best addition to your portfolio.

Illumina (ILMN)

Latest 12-Month GAAP Operating Margin: 18.6%

Illumina (NASDAQ:ILMN) has revolutionized genetic research by making genome sequencing faster and more affordable. The company provides advanced DNA sequencing and microarray solutions, empowering scientists and clinicians to study genetic variation and function.

Concerns About ILMN:

• Organic sales growth over the last two years suggests the company may need to rethink its strategy or pursue acquisitions to accelerate expansion.
• Annual earnings per share have grown just 1.5% over five years, trailing revenue growth, partly due to shareholder dilution.
• Low returns on capital indicate ongoing challenges in deploying resources effectively.

Illumina is currently valued at $124.81 per share, with a forward P/E of 25. Read our full research report to understand why caution is warranted with ILMN.

Our Preferred Stock Picks

ONE MORE THING: This Week’s Top 6 Stocks. The current market is quickly distinguishing true quality from overpriced names. With AI shaking up entire industries overnight, you need more than just a list of solid companies to stay ahead.

Our AI-driven system identified Palantir before its 1,662% surge, AppLovin before a 753% rally, and Nvidia ahead of its 1,178% climb. Every week, it highlights six new stocks that meet our rigorous criteria. Access our Top 6 Stocks for Free HERE.

Past picks from 2020 include household names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Exlservice, which delivered a 354% five-year return. Find your next breakout stock with StockStory today.